• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neck dissection and stroke in patients with oral cavity cancer: A population‐based cohort study
ConclusionOur data demonstrate that neck dissection does not increase the risk of stroke in patients with oral cavity cancer. Patients have higher risk of stroke after cancer treatment because of their older age, specific comorbidities, and/or type of postoperative treatment. © 2016 Wiley Periodicals, Inc. Head Neck, 2016
Source: Head and Neck - July 19, 2016 Category: ENT & OMF Authors: Chia‐Fan Chang, Yen‐Ling Kuo, Christy Pu, Yiing‐Jenq Chou Tags: Original Article Source Type: research

Neck dissection and stroke in patients with oral cavity cancer: A population ‐based cohort study
ConclusionOur data demonstrate that neck dissection does not increase the risk of stroke in patients with oral cavity cancer. Patients have higher risk of stroke after cancer treatment because of their older age, specific comorbidities, and/or type of postoperative treatment. © 2016 Wiley Periodicals, Inc. Head Neck, 2016
Source: Head and Neck - July 19, 2016 Category: ENT & OMF Authors: Chia ‐Fan Chang, Yen‐Ling Kuo, Christy Pu, Yiing‐Jenq Chou Tags: Original Article Source Type: research

Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy.
Abstract Although previous studies demonstrated the risk of ischemic stroke (IS) in patients with head and neck cancer (HNC), the impact of oral antithrombotic therapy (OAT) on this risk has not yet been assessed. We aimed to evaluate the effectiveness and safety of OAT in patients with HNC treated with RT. This retrospective cohort study was performed using the National Health Insurance Research Database of Taiwan. A total of 37,638 patients diagnosed with HNC included in the study were classified as users and nonusers of OAT. Primary outcome was IS or transient ischemic attack (TIA), and secondary outcomes were ...
Source: Biomed Res - December 20, 2016 Category: Research Authors: Hsu CW, Huang YB, Kuo CC, Chen CY Tags: Biomed Res Int Source Type: research

Oral hypoglycemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lowered risk of non‐fatal CV events than those taking glyburide. This article is protected by copyright. All rights reserved.
Source: Diabetes/Metabolism Research and Reviews - July 1, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research

Oral hypoglycaemic agents and the development of non‐fatal cardiovascular events in patients with type 2 diabetes mellitus
ConclusionsT2DM patients taking metformin and glimepiride are at lower risk of non‐fatal cardiovascular events than those taking glyburide. Copyright © 2013 John Wiley & Sons, Ltd.
Source: Diabetes/Metabolism Research and Reviews - November 14, 2013 Category: Endocrinology Authors: Yi‐Chih Hung, Che‐Chen Lin, Tzu‐Yuan Wang, Man‐Ping Chang, Fung‐Chang Sung, Ching‐Chu Chen Tags: Research Article Source Type: research

Atrial fibrillation, CHA2DS2-VASc score, antithrombotics and risk of non-traffic-, non-cancer-related bone fractures: A population-based cohort study.
CONCLUSION: Patients with AF are more vulnerable to non-traffic-, non-cancer-related bone fractures especially when with specified characteristics. For those with higher CHA2DS2-VASc scores, the use of anticoagulant but not antiplatelet agents could be associated with lower risk of such events. PMID: 26493861 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - October 19, 2015 Category: Internal Medicine Authors: Lai HC, Chien WC, Chung CH, Lee WL, Wu TJ, Wang KY, Liu CN, Liu TJ Tags: Eur J Intern Med Source Type: research

Free Tissue Transfers for Head and Neck Reconstruction in Patients with End-Stage Renal Disease on Dialysis: Analysis of Outcomes Using the Taiwan National Health Insurance Research Database
Conclusion Despite greater preoperative risk factors, patients with renal failure on hemodialysis do not appear to have a higher rate of free flap failure following head and neck reconstruction. However, other complications can be minimized by optimizing patient's medical condition to succeed with this reconstructive effort. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Journal of Reconstructive Microsurgery - June 16, 2017 Category: Surgery Authors: Manrique, Oscar J. Ciudad, Pedro Sharaf, Basel Martinez-Jorge, Jorys Moran, Steven Mardini, Samir Chen, Hung-Chi Bite, Uldis Cheng, Hsu-Tang Tags: Original Article Source Type: research

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news